Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward F Patz

Showing results (21-30 of 101) with videos related to

Pageof 11
Sort By:
Cancer|July 9, 2004
Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinomaNayela Khan, Charles J Cromer, Michael Campa, et al.
Radiology|May 9, 2002
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PETEdith M Marom, Sarah Sarvis, James E Herndon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2007
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrenceJoerg Gauger, Edward F Patz, R Edward Coleman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 24, 2015
Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography"Woocheol Kwon, Brandon A Howard, James E Herndon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 27, 2015
FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung CancerWoocheol Kwon, Brandon A Howard, James E Herndon, et al.
Cancer Immunology, Immunotherapy : CII|February 26, 2025
A tumor-binding antibody with cross-reactivity to viral antigensMichael J Campa, Elizabeth B Gottlin, Kevin Wiehe, et al.
Cancer|January 2, 2009
Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survivalKatherine R Birchard, Jenny K Hoang, James E Herndon, et al.
Analytical Biochemistry|September 29, 2004
Accentuation of differentially expressed proteins using phage technologyR Lee Suber, Vincent L Flanders, Michael J Campa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 28, 2017
Rethinking Autoantibody Signature Panels for Cancer DiagnosisMichael J Campa, Elizabeth B Gottlin, James E Herndon, et al.
Seminars in Oncology|February 12, 2002
The role of imaging in malignant pleural mesotheliomaEdith M Marom, Jeremy J Erasmus, Harvey I Pass, et al.
Pageof 11

Showing results (21-30 of 101) with videos related to

Sort By:
Pageof 11
Cancer|July 9, 2004
Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinomaNayela Khan, Charles J Cromer, Michael Campa, et al.
Radiology|May 9, 2002
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PETEdith M Marom, Sarah Sarvis, James E Herndon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2007
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrenceJoerg Gauger, Edward F Patz, R Edward Coleman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 24, 2015
Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography"Woocheol Kwon, Brandon A Howard, James E Herndon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 27, 2015
FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung CancerWoocheol Kwon, Brandon A Howard, James E Herndon, et al.
Cancer Immunology, Immunotherapy : CII|February 26, 2025
A tumor-binding antibody with cross-reactivity to viral antigensMichael J Campa, Elizabeth B Gottlin, Kevin Wiehe, et al.
Cancer|January 2, 2009
Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survivalKatherine R Birchard, Jenny K Hoang, James E Herndon, et al.
Analytical Biochemistry|September 29, 2004
Accentuation of differentially expressed proteins using phage technologyR Lee Suber, Vincent L Flanders, Michael J Campa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 28, 2017
Rethinking Autoantibody Signature Panels for Cancer DiagnosisMichael J Campa, Elizabeth B Gottlin, James E Herndon, et al.
Seminars in Oncology|February 12, 2002
The role of imaging in malignant pleural mesotheliomaEdith M Marom, Jeremy J Erasmus, Harvey I Pass, et al.
Pageof 11